Definium Therapeutics Inc

Definium Therapeutics CEO’s RSU sale shows routine liquidity, not confidence loss; focus on upcoming clinical milestones and investor day for real value shifts.

Definium Therapeutics’ insider sales, routine tax‑cover moves, highlight CEO, CMO, and CLO confidence amid strong psychedelic‑drug results, FDA fast‑track status, and future Phase 3 plans that could boost valuation.

Definium insider buying signals management confidence amid quiet volatility—what it means for investors, dilution risks, and upcoming clinical milestones.